Advances in imaging technologies and analysis tools provide increasingly sophisticated methods for the evaluation and treatment of metabolic diseases. For example, the use of quantitative Computed Tomography (QCT) enables the selective measurement of bone compartments and the evaluation of sub-anatomical Bone Mineral Density (BMD) distribution.
The precise evaluation of the safety of new therapies continues to evolve with the introduction and validation of sophisticated quantitative endpoints for the evaluation of BMD and bone architecture in patients. Bioclinica's metabolic and endocrinology team have experience with the latest advancements in medical imaging and the expertise to implement the newest imaging endpoints. In support of novel endpoint measurements, Bioclinica is pioneering the development of a new technique called 'quadrant analysis' to facilitate fracture risk assessment in Type 2 Diabetes trials.
Imaging Endpoint Analysis
|Endpoint/Outcome Measure||Modalities||Description/Indications||Sample Indication|
|Fatty infiltration||CT, MRI||Evaluation of fat infiltration of liver tissue||Obesity, Fatty Liver Disease and Steatohepatitis|
|Hip Structural Analysis (HSA)||DXA, QCT||Evaluation of femur bending strength||Hyperparathyroidism|
|Bone Mineral Density (BMD)||DXA||Identification of bone loss and fracture risk||Diabetes, Endometriosis, Acne (safety), Androgen deficiency|
|Body Composition||CT, DXA, MRI||Analysis of muscle mass and fatty tissue||Obesity, Diabetes, Cachexia|
|IntraMuscular Adipose Tissue (IMAT)||DXA, MRI||Evaluation of fatty tissue located within muscle||Diabetes, Growth Hormone replacement, Myostatin Inhibitors|
|Muscle volume||DXA, CT, MRI||Measurement of muscle volumes||Sarcopenia|
|Quadrant Analysis||QCT||Evaluation of the four quadrants of the femoral neck cortical shell for both volumetric BMD and thickness||Diabetes|
|Subcutaneous Adipose Tissue (SAT)||CT, DXA, MRI||Evaluation of non-visceral fat below the skin||Obesity, Cachexia, Diabetes|
|Total Adipose Tissue (TAT)||CT, DXA, MRI||Evaluation of total body fat tissue||Obesity, Cachexia, Diabetes|
|Visceral Adipose Tissue (VAT)||CT, DXA, MRI||Evaluation of fat present between major organs||Obesity, Diabetes|
|Examples of common endpoints and modalities used in clinical trials for metabolic and endocrine diseases|
As part of our dedication to quality service, we have developed and utilize imaging phantoms for qualification of DXA instruments used in clinical trials.
- The BonaFide DXA Phantom (BFP) enables instrument verification over a clinically relevant range of bone mineral densities (BMDs).
- The Bioclinica Body Composition Phantom (BBCP) enables monitoring of machine drift and simulates different soft tissue and bone compositions.